Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

62 results about "AN - Anorexia nervosa" patented technology

Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low weight, fear of gaining weight, and a strong desire to be thin, resulting in food restriction.

Cytokine antagonists for neurological and neuropsychiatric disorders

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, postpartum depression, and schizoaffective illness.
Owner:TACT IP

Method for treating cachexia with retinoid ligands

The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.
Owner:JIANG GUANG LIANG +2

Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof

InactiveUS20060111386A1BiocideAnimal repellantsAcute Stress DisorderSleep Related Eating Disorder
The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.
Owner:ALBANY MOLECULAR RESEARCH INC

Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof

Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH

Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them

ActiveUS20080132486A1Easily determining tailoringSimple designBiocideNervous disorderDiseaseAlcoholisms
One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1

Cytokine antagonists for neurological and neuropsychiatric disorders

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, post-partum depression, and schizoaffective illness.
Owner:TACT IP

Application of bifidobacterium lactis in prevention and treatment of mental disorder

The invention relates to application of bifidobacterium lactis in prevention and treatment of mental disorder, the bifidobacterium lactis is bifidobacterium lactis BL-11, and the preservation number of the bifidobacterium lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The bifidobacterium lactis provided by the invention can be used for improving the intestinal permeability and reducing the levels of LPS and D-lactic acid in blood, so that the effect of preventing and treating mental disorders is achieved, and the mental disorders comprise anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette disease and Escherberg syndrome.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

Serotonin and norepinephrine reuptake inhibitor and uses thereof

InactiveUS20070015824A1Low level of undesirable side-effectsBiocideOrganic chemistryNorepinephrine reuptake inhibitorDepressant
Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH

Cytokine antagonists for neurological and neuropsychiatric disorders

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additionally, intranasal administration is discussed as a method to provide therapeutic benefit.The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathetic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawal, post-partum depression, and schizoaffective illness.
Owner:TACT IP

Composition and formulations and their use as nociceptic, anti-axniolytic and anabolic agents

Composition and formulations comprising a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s) such as analgesics, muscle relaxants, mood disorder agents, anti-inflammatories, anti-migraine agents, anti-emetics, diuretics, high protein composites, and the like. The products are suitable as nociceptics and for the treatment of wasting disorders, bulimia, anorexia nervosa, anxiety, irritability and other symptoms associated with Pre Menstrual Syndrome, as well as for administration either in conjunction with steroids or to compensate adenosine depletion and / or bizarre behavior or aggression common in steroid users.
Owner:EAST CAROLINA UNIVERISTY

CB1 antagonists and inverse agonists

InactiveUS20080027087A1Minimizing metabolic risk factorEfficient dosingBiocideOrganic chemistryMetabolic syndromeAN - Anorexia nervosa
The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.
Owner:AMPLA PHARMA

Method of screening preventives or remedies for obesity

The present invention provides preventive / therapeutic agents for anorexia nervosa and preventive / therapeutic agents for obesity. More specifically, the present invention provides a method and kit for screening a compound or its salt that changes the binding properties of GPR7 to a polypeptide capable of binding specifically to GPR7.
Owner:TAKEDA PHARMA CO LTD

Traditional Chinese medicine mixture for treating anorexia nervosa

The invention discloses a traditional Chinese medicine mixture for treating anorexia nervosa. The mixture is prepared from the following medicinal materials in parts by weight: 6-9 parts of oroxylum indicum, 1-3 parts of neroli, 5-8 parts of semen aesculi, 6-9 parts of tribulus terrestris, 1-3 parts of peganum harmala, 6-9 parts of peliosanthestetaandr, 15-20 parts of mariscus umbellatus, 12-15 parts of conespike flemingia roots, 10-12 parts of green fig roots, 15-20 parts of polygonum posumbu, 1-3 parts of herpetospermum seeds, 9-12 parts of elaeagnus pungens, 12-15 parts of blueflower cicerbita roots, 12-15 parts of Siberian nitraria fruits, 9-12 parts of dwarf cowlily seeds, 9-12parts of caesalpinia, 15-20 parts of phaenosperma globosa, 9-12 parts of bilobate grewia, 12-15 parts of roots of white flowered bittercress and 5-7 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention for treating liver-stagnation with spleen-deficiency type anorexia nervosa is high in effective rate and reliable in curative effect and anorexia nervosa does not relapse after being healed.
Owner:JINING UNIV

Medicinal composition for treating anorexia nervosa

The invention discloses a medicinal composition for treating anorexia nervosa, which consists of extracts of red infested rice, Chinese thorowax root and epimedium herb. The extracts are prepared by the prior method, comprise but are not limited to aqueous extract, alcohol extract, macroporous resin column extract by water extraction and alcohol sedimentation or a supercritical extraction method. The medicinal composition is added with the prior accessories and made into clinically acceptable medicament formulations according to the prior process. The medicinal composition has remarkable effect of treating the anorexia nervosa and no side effects.
Owner:BEIJING WBL PEKING UNIV BIOTECH

CB1 antagonists and inverse agonists

InactiveUS20090036426A1Minimizing metabolic risk factorMinimize risk factorBiocideMetabolism disorderMetabolic syndromeAN - Anorexia nervosa
The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention conjointly with zonisamide, naltrexone, or a pharmaceutically acceptable salt thereof. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention conjointly with zonisamide, naltrexone, or a pharmaceutically acceptable salt thereof.
Owner:AMPLA PHARMA

2-halo-5-alkynyl-pyridyl nicotinic ligands

Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.
Owner:GEORGETOWN UNIV

2-Halo-5-ynyl-pyridylnicotinyl ligands

Heterocyclic compounds that are ligands for nicotinic acetylcholine receptors are disclosed. The compounds are useful in the treatment of mammals suffering from any of a variety of therapeutic indications including Alzheimer's disease, Parkinson's disease, movement disorders, Tourette's syndrome , Schizophrenia, Attention Deficit Disorder, Anxiety, Pain, Depression, Compulsive Disorder, Substance Abuse, Alcoholism, Amnesia, Pseudodementia, Gunther Syndrome, Migraine, Bulimia, Obesity, Menstrual Pre or LPS, Tobacco Abuse, Post Traumatic Syndrome, Social Phobia, Chronic Fatigue Syndrome, Premature Ejaculation, Erectile Dysfunction, Anorexia Nervosa, Sleep Disorders, Autism, Mutism, Trichotillomania, and Hypothyroidism body temperature.
Owner:GEORGETOWN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products